Cost of Cystic Fibrosis: Analysis of Treatment Costs in a Specialized Center in Northern Italy

Colombo, Carla; Daccò, Valeria; Alicandro, Gianfranco; Loi, Silvana; Mazzi, S.; Lucioni, Carlo; Ravasio, Roberto

doi:10.1007/s12325-013-0008-5

Cited by 14 publications

(5 citation statements)

References 24 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following medication, there was an emphasis on financial burden or the cost of treatment for participants and their families. For example, Colombo et al [ 40 ] examined the medical costs (i.e. hospitalizations, outpatient medical interventions, medication, devices and dietetic products) associated with treating cystic fibrosis in Italy.…”

Section: Resultsmentioning

confidence: 99%

“…Within Group 2, there was significant interest in understanding the burden of treatment for cystic fibrosis, for children, adolescents, adults, and parents [ 36 , 40 , 52 – 54 , 57 , 65 , 75 ]. A total of 12 Group 2 papers focused on cystic fibrosis, although the study by Ziaian et al [ 68 ] also included participants with asthma and diabetes.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature

Sav

Salehi

Mair

et al. 2017

BMC Med Res Methodol

View full text Add to dashboard Cite

BackgroundAlthough there has been growing research on the burden of treatment, the current state of evidence on measuring this concept is unknown. This scoping review aimed to provide an overview of the current state of knowledge as well as clear recommendations for future research, within the context of chronic disease.MethodsFour health-based databases, Scopus, CINAHL, Medline, and PsychInfo, were comprehensively searched for peer-reviewed articles published between the periods of 2000–2016. Titles and abstracts were independently read by two authors. All discrepancies between the authors were resolved by a third author. Data was extracted using a standardized proforma and a comparison analysis was used in order to explore the key treatment burden measures and categorize them into three groups.ResultsDatabase searching identified 1458 potential papers. After removal of duplications, and irrelevant articles by title, 1102 abstracts remained. An additional 22 papers were added via snowball searching. In the end, 101 full papers were included in the review. A large number of the studies involved quantitative measures and conceptualizations of treatment burden (n = 64; 63.4%), and were conducted in North America (n = 49; 48.5%). There was significant variation in how the treatment burden experienced by those with chronic disease was operationalized and measured.ConclusionDespite significant work, there is still much ground to cover to comprehensively measure treatment burden for chronic disease. Greater qualitative focus, more research with cultural and minority populations, a larger emphasis on longitudinal studies and the consideration of the potential effects of “identity” on treatment burden, should be considered.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature

Sav

Salehi

Mair

et al. 2017

BMC Med Res Methodol

View full text Add to dashboard Cite

show abstract

“…ranging from 12% to 77%) according to country and patient characteristics. 23,24 In the United States, an analysis of the 2007 Nationwide Inpatient Sample database estimated that total hospital charges for adults (18-44 years) with CF averaged US$ 53,095 to US$ 59,627, depending on the type of hospital. 25 Thus, reducing CF-related hospitalizations might be expected to reduce overall CFrelated health-care costs.…”

Section: Discussionmentioning

confidence: 99%

Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy

Trapnell

Khurmi

et al. 2020

Chron Respir Dis

View full text Add to dashboard Cite

We investigated the relationship between self-reported adherence to pancreatic enzyme replacement therapy (PERT), nutritional status, and all-cause hospitalization in cystic fibrosis (CF) patients with a record of PERT use. Association of self-reported annual PERT use rate (adherence) with annual hospital admission rate (HAR) and annual total hospital nights (THNs) were analyzed for 5301 children (2000–2012) and 13,989 adults (2000–2013) from the CF Foundation Patient Registry. Multivariate linear regression was used to determine the association of HAR and THN with mean annual PERT use rate, cumulative PERT use rate, mean body mass index (BMI) (adult) or BMI percentile (pediatric), age, and sex. The median annual PERT use rate was 87% in children and 80% in adults. Statistically, higher annual PERT use, longer cumulative PERT, and higher BMI percentile (children) or BMI (adults) were significantly ( p < 0.0001) associated with lower annual HAR and fewer annual THN in children and adults. Female sex was associated with higher annual HAR and more annual THN in children and adults ( p < 0.05). Results indicate self-reported adherence to PERT, increased BMI, and male sex were associated with fewer hospital admissions and annual hospital nights in CF patients.

show abstract

“…In CF, contrary to other genetic diseases (for example beta thalassemia), the identification of carriers is possible only through molecular research of CFTR mutations. A recent report has shown the costs of managing CF for the Italian National Health System [ 16 ]. The results reports a high cost for the chronic and evolutive aspects of the disease.…”

Section: Discussionmentioning

confidence: 99%

Analysis of cystic fibrosis gene mutations in children with cystic fibrosis and in 964 infertile couples within the region of Basilicata, Italy: a research study

et al. 2014

View full text Add to dashboard Cite

IntroductionCystic fibrosis is the most common autosomal recessive genetic disease in the Caucasian population. Extending knowledge about the molecular pathology on the one hand allows better delineation of the mutations in the CFTR gene and the other to dramatically increase the predictive power of molecular testing.MethodsThis study reports the results of a molecular screening of cystic fibrosis using DNA samples of patients enrolled from January 2009 to December 2013. Patients were referred to our laboratory for cystic fibrosis screening for infertile couples. In addition, we identified the gene mutations present in 76 patients affected by cystic fibrosis in the pediatric population of Basilicata.ResultsIn the 964 infertile couples examined, 132 subjects (69 women and 63 men) resulted heterozygous for one of the CFTR mutations, with a recurrence of carriers of 6.85%. The recurrence of carriers in infertile couples is significantly higher from the hypothetical value of the general population (4%).ConclusionsThis study shows that in the Basilicata region of Italy the CFTR phenotype is caused by a small number of mutations.Our aim is to develop a kit able to detect not less than 96% of CTFR gene mutations so that the relative risk for screened couples is superimposable with respect to the general population.

show abstract

Cost of Cystic Fibrosis: Analysis of Treatment Costs in a Specialized Center in Northern Italy

Cited by 14 publications

References 24 publications

Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature

Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature

Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy

Analysis of cystic fibrosis gene mutations in children with cystic fibrosis and in 964 infertile couples within the region of Basilicata, Italy: a research study

Contact Info

Product

Resources

About